Talquetamab是一种GPRC5D×CD3双特异性抗体，用于中国复发/难治性多发性骨髓瘤患者：来自1/2期monument -1研究的有效性和安全性

IF 7.9 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-10-09 DOI:10.3324/haematol.2025.287334

Gang An,Jie Jin,Zhen Cai,Hongmei Jing,Chengcheng Fu,Pengcheng He,Zhongjun Xia,Rui Liu,Liang Li,Xue Gai,Hong Zhang,Dian Zhu,Xinchao Luo,Binbin Sun,Hongmei Xu,Longen Zhou,Michela Campagna,Tara J Masterson,Bonnie W Lau,Thomas Renaud,Christoph Heuck,Indrajeet Singh,Deeksha Vishwamitra,Lugui Qiu

引用次数: 0

摘要

不可用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study.

Not available.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.